Department of Bioengineering, University of Washington, Seattle, Washington 98195, United States.
Institute for Protein Design, University of Washington, Seattle, Washington 98195, United States.
Bioconjug Chem. 2022 Nov 16;33(11):2018-2034. doi: 10.1021/acs.bioconjchem.2c00030. Epub 2022 Apr 29.
Despite remarkable advances over the past several decades, many therapeutic nanomaterials fail to overcome major in vivo delivery barriers. Controlling immunogenicity, optimizing biodistribution, and engineering environmental responsiveness are key outstanding delivery problems for most nanotherapeutics. However, notable exceptions exist including some lipid and polymeric nanoparticles, some virus-based nanoparticles, and nanoparticle vaccines where immunogenicity is desired. Self-assembling protein nanoparticles offer a powerful blend of modularity and precise designability to the field, and have the potential to solve many of the major barriers to delivery. In this review, we provide a brief overview of key designable features of protein nanoparticles and their implications for therapeutic delivery applications. We anticipate that protein nanoparticles will rapidly grow in their prevalence and impact as clinically relevant delivery platforms.
尽管在过去几十年中取得了显著进展,但许多治疗性纳米材料仍未能克服主要的体内输送障碍。控制免疫原性、优化生物分布和工程环境响应性是大多数纳米治疗剂的关键突出输送问题。然而,也存在显著的例外情况,包括一些脂质和聚合物纳米粒子、一些基于病毒的纳米粒子和纳米疫苗,其中需要免疫原性。自组装蛋白纳米颗粒为该领域提供了强大的模块化和精确设计能力的融合,并有可能解决许多主要的输送障碍。在这篇综述中,我们简要概述了蛋白纳米颗粒的关键可设计特征及其对治疗性输送应用的影响。我们预计,作为临床相关输送平台,蛋白纳米颗粒的流行度和影响力将迅速增长。